Theraclion touts 2-year Echopulse data from breast fibroadenoma study

Theraclion (EPA:ALTHE) this week released 2-year results from a trial of its Echopulse non-invasive ultrasound system for treating breast fibroadenoma. Study results were published in the March 2017 issue of the Journal of Therapeutic Ultrasound, the French company said. The 20 patient study examined the use of the Echopulse system, an ultrasound-guided high-intensity focused ultrasound device, in reducing the volume of 26 breast fibroadenomas, or benign tumors. Data indicated that mean BFA volume was reduced by 77.32% after a single procedure and 90.47% after 2 procedures at 2 years. No cases of re-growth of treated lesions were observed at 2 years, and treatment was well tolerated regardless of the number of sessions performed, researchers said. No serious side effects were observed. “Our results show the long-term efficacy and safety of US-guided HIFU generated by Theraclion’s Echopulse in patients with breast fibroadenomas. US-guided HIFU is definitely an effective non-invasive alternative to surgery enabling more than 90% volume reduction without re-growth or serious adverse events,” principal investigator Dr. Roussanka Kovatcheva of Sofia, Bulgaria’s University Hospital of Endocrinology said in a prepared statement. “The results of this trial provide validation and confirmation of the remarkable and enduring effect of the Echopulse treatment for the breast fibroadenoma indication. In addition, for the first time, results related to the incre...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Ultrasound Women's Health Theraclion Source Type: news